KALA BIO completes Phase 2b enrollment for KPI-012; cash runway into Q1 2026

KALA BIO, Inc.

2025-Q2 EPS reported -$3.13

Net loss $11.2M ($1.71/share) for Q2 2025 vs $9.6M ($3.16) in Q2 2024.
Cash $31.9M as of June 30; expected to fund operations into Q1 2026.
Phase 2b CHASE trial enrolled 79 patients; topline data expected end of September 2025.
R&D expenses $6.2M in Q2, up 17% YoY due to KPI-012 development costs.
Interim CEO says positive results could support a BLA submission to FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.